In a groundbreaking pilot study, researchers have introduced an innovative approach to deep brain stimulation (DBS) that may greatly enhance the lives of individuals with Parkinson’s disease. This technique, referred to as “adaptive” DBS, automatically modifies the level of electrical stimulation delivered to the brain based on real-time signals, potentially offering improved symptom control and a better quality of life.
Traditional DBS involves implanting fine electrodes in specific brain areas that govern movement, providing a constant level of electrical stimulation. While this method can alleviate symptoms such as stiffness, slowness, and tremors, it also risks causing understimulation or overstimulation, leading to either a resurgence of symptoms or erratic movements.
The research team, headed by Dr. Carina Oehrn from the University of California, San Francisco, has developed algorithms that allow the DBS device to detect brain activity and adjust stimulation levels accordingly. By monitoring a specific type of brain signal linked to rising dopamine levels and the alleviation of motor symptoms, the system can increase stimulation when the signal is low and decrease it when the signal is high.
In the pilot study, four men with Parkinson’s who had received a research DBS device were exposed to both traditional DBS and the new adaptive approach for one month each. The results were encouraging, showing that participants experienced about 50% less waking time with their most bothersome symptoms while using adaptive DBS compared to traditional DBS. Additionally, three of the four participants reported an improved quality of life.
While medications will still be necessary alongside adaptive DBS, this new approach could potentially allow for reduced dosages. Dr. Simon Little, another author of the study, highlighted that medications are often essential for managing both mood and movement in Parkinson’s disease and should not be entirely discontinued.
The research team recognizes that further trials are essential to validate the pilot study’s findings, and some adjustments are needed to make the technology practical for everyday clinical use. Nevertheless, they are hopeful that adaptive DBS could evolve into a highly effective alternative to standard DBS for Parkinson’s disease and possibly other neurological and psychiatric disorders within a few years, providing more stable and personalized symptom control at a comparable cost to traditional DBS.
Claire Bale, the associate director of research at Parkinson’s UK, praised the research but emphasized the need for larger clinical trials to confirm the therapy’s safety and effectiveness, which is crucial for adaptive DBS to receive approval as a new treatment option for individuals with Parkinson’s disease.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.